EXICURE, INC. Operating Expenses
EXICURE, INC. (XCUR) reported Operating Expenses of $1.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- EXICURE, INC. operating expenses for the quarter ending 2026-06-30 was $1.05M, a 57.99% decline year-over-year.
- EXICURE, INC. operating expenses for the quarter ending 2026-03-31 was $1.64M.
- EXICURE, INC. operating expenses for the quarter ending 2025-12-31 was $2.26M, a 70.27% decline year-over-year.
- EXICURE, INC. operating expenses for the quarter ending 2025-09-30 was $2.39M, a 7.04% decline year-over-year.
- EXICURE, INC. operating expenses for fiscal 2025 was $4.23M, a 66.75% decline from fiscal 2024.
- EXICURE, INC. operating expenses for fiscal 2024 was $12.73M, a 15.10% decline from fiscal 2023.
- EXICURE, INC. operating expenses for fiscal 2023 was $15.00M, a 51.08% decline from fiscal 2022.
- EXICURE, INC. operating expenses for fiscal 2022 was $30.66M, a 50.61% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.05M 10-Q · filed 2026-08-14 | $2.69M 10-Q · filed 2026-08-14 | $4.95M derived: sum of 3 quarters · filed 2026-08-14 | $7.34M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $1.64M 10-Q · filed 2026-05-29 | $3.90M derived: sum of 2 quarters · filed 2026-05-29 | $6.29M derived: sum of 3 quarters · filed 2026-05-29 | $8.80M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.65M derived: sum of 2 quarters · filed 2026-03-25 | $7.16M derived: sum of 3 quarters · filed 2026-08-14 | $4.23M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $2.39M 10-Q · filed 2025-11-07 | $4.90M derived: sum of 2 quarters · filed 2026-08-14 | $1.98M 10-Q · filed 2025-11-07 | $9.57M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $2.51M 10-Q · filed 2026-08-14 | -$414.00K 10-Q · filed 2026-08-14 | $7.17M derived: sum of 3 quarters · filed 2026-08-14 | $9.75M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$2.92M 10-Q · filed 2026-05-29 | -$2.95M 10-Q · filed 2025-06-27 | $4.67M derived: sum of 2 quarters · filed 2026-05-29 | $7.24M derived: sum of 3 quarters · filed 2026-05-29 | $8.47M derived: sum of 4 quarters · filed 2026-05-29 | ||
| 2024-12-31 | $7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $10.16M derived: sum of 2 quarters · filed 2026-03-25 | $11.40M derived: sum of 3 quarters · filed 2026-03-25 | $12.73M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $2.57M 10-Q · filed 2025-11-07 | $3.81M derived: sum of 2 quarters · filed 2025-11-07 | $5.14M 10-Q · filed 2025-11-07 | $6.64M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $1.24M 10-Q · filed 2025-08-08 | $2.57M 10-Q · filed 2025-08-08 | $4.07M derived: sum of 3 quarters · filed 2025-08-08 | $7.39M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | $1.34M 10-Q · filed 2025-06-27 | $2.83M derived: sum of 2 quarters · filed 2025-06-27 | $6.15M derived: sum of 3 quarters · filed 2025-06-27 | $11.79M derived: sum of 4 quarters · filed 2025-06-27 | |||
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $4.82M derived: sum of 2 quarters · filed 2025-03-18 | $10.46M derived: sum of 3 quarters · filed 2025-03-18 | $15.00M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $3.32M 10-Q · filed 2024-11-14 | $8.96M derived: sum of 2 quarters · filed 2024-11-14 | $13.50M 10-Q · filed 2024-11-14 | $16.68M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $5.64M 10-Q · filed 2024-08-13 | $10.18M 10-Q · filed 2024-08-13 | $13.36M derived: sum of 3 quarters · filed 2024-08-13 | $20.58M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $4.54M 10-Q · filed 2024-06-17 | $7.72M derived: sum of 2 quarters · filed 2024-06-17 | $14.94M derived: sum of 3 quarters · filed 2024-06-17 | $24.89M derived: sum of 4 quarters · filed 2024-06-17 | |||
| 2022-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $10.40M derived: sum of 2 quarters · filed 2024-06-06 | $20.36M derived: sum of 3 quarters · filed 2024-06-06 | $30.66M 10-K · filed 2024-06-06 | |||
| 2022-09-30 | $7.22M 10-Q · filed 2024-05-16 | $17.18M derived: sum of 2 quarters · filed 2024-06-06 | $27.48M 10-Q · filed 2024-05-16 | $43.04M derived: sum of 4 quarters · filed 2024-06-06 | |||
| 2022-06-30 | $9.95M 10-Q/A · filed 2024-06-06 | $20.26M 10-Q/A · filed 2024-06-06 | $35.82M derived: sum of 3 quarters · filed 2024-06-06 | $55.23M derived: sum of 4 quarters · filed 2024-06-06 | |||
| 2022-03-31 | $10.30M 10-Q/A · filed 2024-06-06 | $25.87M derived: sum of 2 quarters · filed 2024-06-06 | $45.27M derived: sum of 3 quarters · filed 2024-06-06 | $59.21M derived: sum of 4 quarters · filed 2024-06-06 | |||
| 2021-12-31 | $15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $34.97M derived: sum of 2 quarters · filed 2023-03-27 | $48.91M derived: sum of 3 quarters · filed 2023-03-27 | $62.07M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $19.40M 10-Q · filed 2022-11-14 | $33.34M derived: sum of 2 quarters · filed 2022-11-14 | $46.50M 10-Q · filed 2022-11-14 | $59.10M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $13.94M 10-Q · filed 2022-08-15 | $27.09M 10-Q · filed 2022-08-15 | $39.70M derived: sum of 3 quarters · filed 2022-08-15 | $51.26M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $13.15M 10-Q · filed 2022-05-16 | $25.75M derived: sum of 2 quarters · filed 2022-05-16 | $37.32M derived: sum of 3 quarters · filed 2022-05-16 | $46.55M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $24.16M derived: sum of 2 quarters · filed 2022-03-25 | $33.40M derived: sum of 3 quarters · filed 2022-03-25 | $42.05M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | $11.56M 10-Q · filed 2021-11-19 | $20.80M derived: sum of 2 quarters · filed 2021-11-19 | $29.45M 10-Q · filed 2021-11-19 | $39.87M derived: sum of 4 quarters · filed 2021-11-19 | |||
| 2020-06-30 | $9.24M 10-Q · filed 2021-08-12 | $17.89M 10-Q · filed 2021-08-12 | $28.30M derived: sum of 3 quarters · filed 2021-08-12 | $34.78M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $8.65M 10-Q · filed 2021-05-12 | $19.07M derived: sum of 2 quarters · filed 2021-05-12 | $25.54M derived: sum of 3 quarters · filed 2021-05-12 | $30.96M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $10.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $16.89M derived: sum of 2 quarters · filed 2021-03-11 | $22.31M derived: sum of 3 quarters · filed 2021-03-11 | $27.91M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $6.47M 10-Q · filed 2020-11-12 | $11.89M derived: sum of 2 quarters · filed 2020-11-12 | $17.49M 10-Q · filed 2020-11-12 | $22.37M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $5.42M 10-Q · filed 2020-08-12 | $11.02M 10-Q · filed 2020-08-12 | $15.89M derived: sum of 3 quarters · filed 2020-08-12 | $21.82M derived: sum of 4 quarters · filed 2020-08-12 | |||
| 2019-03-31 | $5.60M 10-Q · filed 2020-05-14 | $10.48M derived: sum of 2 quarters · filed 2020-05-14 | $16.40M derived: sum of 3 quarters · filed 2020-05-14 | $22.22M derived: sum of 4 quarters · filed 2020-05-14 | |||
| 2018-12-31 | $4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $10.79M derived: sum of 2 quarters · filed 2020-03-10 | $16.62M derived: sum of 3 quarters · filed 2020-03-10 | $21.94M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $5.92M 10-Q · filed 2019-11-07 | $11.74M derived: sum of 2 quarters · filed 2019-11-07 | $17.06M 10-Q · filed 2019-11-07 | $22.47M derived: sum of 4 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $5.82M 10-Q · filed 2019-08-08 | $11.14M 10-Q · filed 2019-08-08 | $16.55M derived: sum of 3 quarters · filed 2019-09-23 | $20.94M derived: sum of 4 quarters · filed 2019-09-23 | |||
| 2018-03-31 | $5.32M 10-Q · filed 2019-05-08 | $10.73M derived: sum of 2 quarters · filed 2019-09-23 | $15.12M derived: sum of 3 quarters · filed 2019-09-23 | $20.53M derived: sum of 4 quarters · filed 2019-09-23 | |||
| 2017-12-31 | $5.41M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $9.80M derived: sum of 2 quarters · filed 2019-09-23 | $15.21M derived: sum of 3 quarters · filed 2019-09-23 | $20.13M 10-K/A · filed 2019-09-23 | $21.15M 10-K · filed 2018-03-09 | ||
| 2017-09-30 | $4.39M 10-Q · filed 2018-11-06 | $4.77M 10-Q · filed 2017-11-14 | $9.80M derived: sum of 2 quarters · filed 2018-11-06 | $14.72M 10-Q · filed 2018-11-06 | $16.09M 10-Q · filed 2017-11-14 | $20.85M derived: sum of 4 quarters · filed 2018-11-06 | |
| 2017-06-30 | $5.41M 10-Q · filed 2018-08-06 | $10.32M 10-Q · filed 2018-08-06 | $16.46M derived: sum of 3 quarters · filed 2018-08-06 | $19.72M derived: sum of 4 quarters · filed 2018-08-06 | |||
| 2017-03-31 | $4.91M 10-Q · filed 2018-05-15 | $11.05M derived: sum of 2 quarters · filed 2018-05-15 | $14.31M derived: sum of 3 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $9.39M derived: sum of 2 quarters · filed 2018-03-09 | $17.20M 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | $3.26M 10-Q · filed 2017-11-14 | $11.06M 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |